Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
 
(269 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
 
+
<span id="BackToTop"></span>
 +
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
 +
[[#top|Back to Top]]
 +
</div>
 
=Guidelines=
 
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
  
 
'''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.'''
 
'''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.'''
 
==Chemotherapy safety standards==
 
==Chemotherapy safety standards==
  
−
*'''2020:''' Dillmon et al. [https://doi.org/10.1200/JCO.19.02297 Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards] [https://pubmed.ncbi.nlm.nih.gov/31815576 PubMed]
+
*'''2020:''' Dillmon et al. [https://doi.org/10.1200/JCO.19.02297 Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards] [https://pubmed.ncbi.nlm.nih.gov/31815576/ PubMed]
−
*'''2019:''' Celano et al. [https://doi.org/10.1200/JCO.18.01616 Safe handling of hazardous drugs: ASCO standards] [https://pubmed.ncbi.nlm.nih.gov/30620670 PubMed]
+
*'''2019:''' Celano et al. [https://doi.org/10.1200/JCO.18.01616 Safe handling of hazardous drugs: ASCO standards] [https://pubmed.ncbi.nlm.nih.gov/30620670/ PubMed]
 
*'''2016:''' Neuss et al. [https://doi.org/10.1200/JOP.2016.017905 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology]
 
*'''2016:''' Neuss et al. [https://doi.org/10.1200/JOP.2016.017905 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology]
−
*'''2010:''' Carrington et al. [https://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01321.x/full The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy] [https://pubmed.ncbi.nlm.nih.gov/20887505 PubMed]
+
*'''2010:''' Carrington et al. [https://doi.org/10.1111/j.1743-7563.2010.01321.x The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy] [https://pubmed.ncbi.nlm.nih.gov/20887505/ PubMed]
  
 
==Dose adjustments==
 
==Dose adjustments==
 
*'''2021:''' Griggs et al. [https://doi.org/10.1200/jco.21.00471 Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update]
 
*'''2021:''' Griggs et al. [https://doi.org/10.1200/jco.21.00471 Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update]
−
===Older===
+
 
−
*'''2012:''' Griggs et al. [https://doi.org/10.1200/jco.2011.39.9436 Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [https://doi.org/10.1200/jco.2011.39.9436 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22473167 PubMed]</ref>
+
*'''2012:''' Griggs et al. [https://doi.org/10.1200/jco.2011.39.9436 Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [https://doi.org/10.1200/jco.2011.39.9436 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22473167/ PubMed]</ref>
  
 
==Antimicrobials==
 
==Antimicrobials==
Line 24: Line 28:
  
 
=Approved antineoplastics=
 
=Approved antineoplastics=
−
''This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound.''
+
''This section contains anticancer drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound. For drugs first approved within the current or prior calendar years, the date of initial approval is also provided here.''
 
==A==
 
==A==
  
Line 32: Line 36:
 
*[[Acalabrutinib (Calquence)]]
 
*[[Acalabrutinib (Calquence)]]
 
*[[Aclarubicin (Aclacinomycin)]]
 
*[[Aclarubicin (Aclacinomycin)]]
−
*[[Ado-trastuzumab emtansine (Kadcyla)]]
+
*[[Adagrasib (Krazati)]]
 
*[[Afatinib (Gilotrif)]]
 
*[[Afatinib (Gilotrif)]]
 
*[[Aldesleukin (Proleukin)]]
 
*[[Aldesleukin (Proleukin)]]
Line 44: Line 48:
 
*[[Amifostine (Ethyol)]]
 
*[[Amifostine (Ethyol)]]
 
*[[Aminoglutethimide (Cytadren)]]
 
*[[Aminoglutethimide (Cytadren)]]
−
*[[Amivantamab (Rybrevant)]] '''FDA approved 5/21/2021'''
+
*[[Amivantamab (Rybrevant)]]
 
*[[Amrubicin (Calsed)]]
 
*[[Amrubicin (Calsed)]]
 
*[[Amsacrine (Amsidine)]]
 
*[[Amsacrine (Amsidine)]]
 
*[[Anastrozole (Arimidex)]]
 
*[[Anastrozole (Arimidex)]]
 
*[[Ancestim (Stemgen)]]
 
*[[Ancestim (Stemgen)]]
 +
*[[Anlotinib (Fukewei)]]
 
*[[Apalutamide (Erleada)]]
 
*[[Apalutamide (Erleada)]]
 
*[[Apatinib (Aitan)]]
 
*[[Apatinib (Aitan)]]
 
*[[Arsenic trioxide (Trisenox)]]
 
*[[Arsenic trioxide (Trisenox)]]
−
*[[Asciminib (Scemblix)]] '''FDA approved 10/29/2021'''
+
*[[Asciminib (Scemblix)]]
 
*[[Asparaginase Erwinia chrysanthemi (Erwinaze)]]
 
*[[Asparaginase Erwinia chrysanthemi (Erwinaze)]]
−
**[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]] '''FDA approved 6/30/2021'''
+
**[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]]
 
*[[Atezolizumab (Tecentriq)]]
 
*[[Atezolizumab (Tecentriq)]]
 +
*[[Aumolertinib (Amelie)]]
 
*[[Avapritinib (Ayvakit)]]
 
*[[Avapritinib (Ayvakit)]]
 
*[[Avelumab (Bavencio)]]
 
*[[Avelumab (Bavencio)]]
Line 66: Line 72:
  
  
−
*[[Bacillus Calmette-Guérin (BCG)]]
+
*[[BCG vaccine]]
 
*[[Belantamab mafodotin (Blenrep)]]
 
*[[Belantamab mafodotin (Blenrep)]]
 
*[[Belinostat (Beleodaq)]]
 
*[[Belinostat (Beleodaq)]]
 
*[[Belotecan (Camptobell)]]
 
*[[Belotecan (Camptobell)]]
−
*[[Belumosudil (Rezurock)]] '''FDA approved 7/16/2021'''
+
*[[Belumosudil (Rezurock)]]
−
*[[Belzutifan (Welireg)]] '''FDA approved 8/13/2021'''
+
*[[Belzutifan (Welireg)]]
 
*[[Bendamustine]]
 
*[[Bendamustine]]
 
*[[Benralizumab (Fasenra)]]
 
*[[Benralizumab (Fasenra)]]
 
*[[Bevacizumab (Avastin)]]
 
*[[Bevacizumab (Avastin)]]
 +
**[[Bevacizumab-adcd (Vegzelga)]]
 +
**[[Bevacizumab-aveg (Avegra)]]
 
**[[Bevacizumab-awwb (Mvasi)]]
 
**[[Bevacizumab-awwb (Mvasi)]]
 +
**[[Bevacizumab-aybi (Aybintio)]]
 
**[[Bevacizumab-bvzr (Zirabev)]]
 
**[[Bevacizumab-bvzr (Zirabev)]]
−
**[[Bevacizumab (Alymsys/Oyavas)]]
+
**[[Bevacizumab-equi (Equidacent)]]
−
**[[Bevacizumab (Aybintio)]]
+
**[[Bevacizumab-maly (Alymsys)]]
−
**[[Bevacizumab (Equidacent)]]
+
**[[Bevacizumab-onbe (Onbevzi)]]
−
**[[Bevacizumab (Onbevzi)]]
+
**[[Bevacizumab-tnjn (Avzivi)]] '''FDA approved 2023-12'''
 
*[[Bexarotene (Targretin)]]
 
*[[Bexarotene (Targretin)]]
 
*[[Bicalutamide (Casodex)]]
 
*[[Bicalutamide (Casodex)]]
−
*[[Binimetinib (Mektovi)]]
+
*[[Binimetinib (Mektovi)]]
 
*[[Bleomycin (Blenoxane)]]
 
*[[Bleomycin (Blenoxane)]]
 
*[[Blinatumomab (Blincyto)]]
 
*[[Blinatumomab (Blincyto)]]
 +
*[[Borofalan-10B (Steboronine)]]
 
*[[Bortezomib (Velcade)]]
 
*[[Bortezomib (Velcade)]]
 
*[[Bosutinib (Bosulif)]]
 
*[[Bosutinib (Bosulif)]]
Line 101: Line 111:
 
*[[Cabozantinib (Cometriq)]]
 
*[[Cabozantinib (Cometriq)]]
 
*[[Calaspargase (Asparlas)]]
 
*[[Calaspargase (Asparlas)]]
 +
*[[Camrelizumab (AiRuiKa)]]
 
*[[Capecitabine (Xeloda)]]
 
*[[Capecitabine (Xeloda)]]
 +
*[[Capivasertib (Truqap)]] '''FDA approved 2023-11-16'''
 
*[[Caplacizumab (Cablivi)]]
 
*[[Caplacizumab (Cablivi)]]
 
*[[Capmatinib (Tabrecta)]]
 
*[[Capmatinib (Tabrecta)]]
 
*[[Carboplatin (Paraplatin)]]
 
*[[Carboplatin (Paraplatin)]]
 
*[[Carfilzomib (Kyprolis)]]
 
*[[Carfilzomib (Kyprolis)]]
 +
*[[Carmofur (HCFU)]]
 
*[[Carmustine (BCNU)]]
 
*[[Carmustine (BCNU)]]
 
*[[Carmustine wafer, polifeprosan 20 (Gliadel)]]
 
*[[Carmustine wafer, polifeprosan 20 (Gliadel)]]
−
*[[Caspofungin (Cancidas)]]
 
 
*[[Cemiplimab (Libtayo)]]
 
*[[Cemiplimab (Libtayo)]]
 
*[[Ceritinib (Zykadia)]]
 
*[[Ceritinib (Zykadia)]]
Line 115: Line 127:
 
*[[Chlorambucil (Leukeran)]]
 
*[[Chlorambucil (Leukeran)]]
 
*[[Chlorozotocin (DCNU)]]
 
*[[Chlorozotocin (DCNU)]]
−
*[[Ciltacabtagene autoleucel (Carvykti)]] '''FDA approved 3/1/2022'''
+
*[[Ciltacabtagene autoleucel (Carvykti)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cisplatin (Platinol)]]
 
*[[Cladribine (Leustatin)]]
 
*[[Cladribine (Leustatin)]]
Line 138: Line 150:
 
*[[Daratumumab (Darzalex)]]
 
*[[Daratumumab (Darzalex)]]
 
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]]
 
*[[Daratumumab and hyaluronidase (Darzalex Faspro)]]
 +
*[[Daratumumab and vorhyaluronidase (Darzquro)]]
 +
*[[Darinaparsin (Darvias)]]
 
*[[Darolutamide (Nubeqa)]]
 
*[[Darolutamide (Nubeqa)]]
 
*[[Dasatinib (Sprycel)]]
 
*[[Dasatinib (Sprycel)]]
Line 146: Line 160:
 
*[[Dexamethasone (Decadron)]]
 
*[[Dexamethasone (Decadron)]]
 
*[[Dinutuximab (Unituxin)]]
 
*[[Dinutuximab (Unituxin)]]
 +
*[[Dinutuximab beta (Qarziba)]]
 
*[[Docetaxel (Taxotere)]]
 
*[[Docetaxel (Taxotere)]]
−
*[[Dostarlimab (Jemperli)]] '''FDA approved 4/22/2021'''
+
*[[Donafenib (Zepsun)]]
 +
*[[Dostarlimab (Jemperli)]]
 
*[[Doxifluridine (Didox)]]
 
*[[Doxifluridine (Didox)]]
 
*[[Doxorubicin (Adriamycin)]]
 
*[[Doxorubicin (Adriamycin)]]
−
*[[Pegylated liposomal doxorubicin (Doxil)]]
 
 
*[[Durvalumab (Imfinzi)]]
 
*[[Durvalumab (Imfinzi)]]
 
*[[Dutasteride (Avodart)]]
 
*[[Dutasteride (Avodart)]]
Line 156: Line 171:
  
 
==E==
 
==E==
−
 
+
*[[Eflornithine (Iwilfin)]] '''FDA approved 2023-12-13'''
−
 
+
*[[Elacestrant (Orserdu)]] '''FDA approved 2023-01-27'''
 
*[[Elotuzumab (Empliciti)]]
 
*[[Elotuzumab (Empliciti)]]
 +
*[[Elranatamab (Elrexfio)]] '''FDA approved on 2023-08-14'''
 
*[[Emapalumab (Gamifant)]]
 
*[[Emapalumab (Gamifant)]]
 
*[[Enasidenib (Idhifa)]]
 
*[[Enasidenib (Idhifa)]]
 
*[[Encorafenib (Braftovi)]]
 
*[[Encorafenib (Braftovi)]]
 
*[[Enfortumab vedotin (Padcev)]]
 
*[[Enfortumab vedotin (Padcev)]]
 +
*[[Ensartinib (Ensacove)]]
 
*[[Entrectinib (Rozlytrek)]]
 
*[[Entrectinib (Rozlytrek)]]
 +
*[[Envafolimab (Enweida)]]
 
*[[Enzalutamide (Xtandi)]]
 
*[[Enzalutamide (Xtandi)]]
 +
*[[Epcoritamab (Epkinly)]] '''FDA approved 2023-05-19'''
 
*[[Epirubicin (Ellence)]]
 
*[[Epirubicin (Ellence)]]
 
*[[Erdafitinib (Balversa)]]
 
*[[Erdafitinib (Balversa)]]
Line 176: Line 195:
  
 
==F==
 
==F==
−
 
+
*[[Fadrozole (Afema)]]
−
*[[Fam-trastuzumab deruxtecan (Enhertu)]]
 
 
*[[Fedratinib (Inrebic)]]
 
*[[Fedratinib (Inrebic)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Fludarabine (Fludara)]]
 
*[[Fludarabine (Fludara)]]
 +
*[[Flumatinib (Xinfu)]]
 
*[[Flutamide (Eulexin)]]
 
*[[Flutamide (Eulexin)]]
−
*[[Folinic acid (Leucovorin)]]
+
*[[Leucovorin (Folinic acid)]]
 
*[[Forodesine (Fodosine)]]
 
*[[Forodesine (Fodosine)]]
 
*[[Fostamatinib (Tavalisse)]]
 
*[[Fostamatinib (Tavalisse)]]
 
*[[Fotemustine (Muphoran)]]
 
*[[Fotemustine (Muphoran)]]
 +
*[[Fruquintinib (Elunate)]]
 
*[[Fulvestrant (Faslodex)]]
 
*[[Fulvestrant (Faslodex)]]
 +
*[[Furmonertinib (Ivesa)]]
 +
*[[Futibatinib (Lytgobi)]]
  
 
==G==
 
==G==
Line 197: Line 219:
 
*[[Gilteritinib (Xospata)]]
 
*[[Gilteritinib (Xospata)]]
 
*[[Glasdegib (Daurismo)]]
 
*[[Glasdegib (Daurismo)]]
 +
*[[Glofitamab (Columvi)]] '''FDA approved 2023-06-15'''
 
*[[Goserelin (Zoladex)]]
 
*[[Goserelin (Zoladex)]]
  
 
==H==
 
==H==
−
 
+
*[[Heptaplatin (SunPla)]]
−
 
+
*[[Histamine dihydrochloride (Ceplene)]]
−
*[[Heptaplatin (Sunpla)]]
 
 
*[[Histrelin (Vantas)]]
 
*[[Histrelin (Vantas)]]
 
*[[Hydrocortisone (Cortef)]]
 
*[[Hydrocortisone (Cortef)]]
Line 214: Line 236:
 
*[[Icotinib (Conmana)]]
 
*[[Icotinib (Conmana)]]
 
*[[Idarubicin (Idamycin)]]
 
*[[Idarubicin (Idamycin)]]
−
*[[Idecabtagene vicleucel (Abecma)]] '''FDA approved 3/26/2021'''
+
*[[Idecabtagene vicleucel (Abecma)]]
 
*[[Idelalisib (Zydelig)]]
 
*[[Idelalisib (Zydelig)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Imatinib (Gleevec)]]
 
*[[Imatinib (Gleevec)]]
−
*[[Infigratinib (Truseltiq)]] '''FDA approved 5/28/2021'''
+
*[[Imetelstat (Rytelo)]] '''FDA approved 2024-06-06'''
 +
*[[Infigratinib (Truseltiq)]]
 
*[[Inotuzumab ozogamicin (Besponsa)]]
 
*[[Inotuzumab ozogamicin (Besponsa)]]
 
*[[Interferon alfa-2a (Roferon-A)]]
 
*[[Interferon alfa-2a (Roferon-A)]]
 
*[[Interferon alfa-2b (Intron-A)]]
 
*[[Interferon alfa-2b (Intron-A)]]
 +
*[[Interferon gamma-1a (Imunomax-γ)]]
 
*[[Interferon gamma-1b (Actimmune)]]
 
*[[Interferon gamma-1b (Actimmune)]]
 
*[[Iobenguane I 131 (Azedra)]]
 
*[[Iobenguane I 131 (Azedra)]]
 
*[[Iodine-131]]
 
*[[Iodine-131]]
 
*[[Ipilimumab (Yervoy)]]
 
*[[Ipilimumab (Yervoy)]]
−
*[[Iptacopan (LNP023)]]
 
 
*[[Irinotecan (Camptosar)]]
 
*[[Irinotecan (Camptosar)]]
 
*[[Irinotecan liposome (Onivyde)]]
 
*[[Irinotecan liposome (Onivyde)]]
Line 245: Line 268:
 
*[[Lapatinib (Tykerb)]]
 
*[[Lapatinib (Tykerb)]]
 
*[[Larotrectinib (Vitrakvi)]]
 
*[[Larotrectinib (Vitrakvi)]]
−
*[[Lasofoxifene (Fablyn)]] '''not FDA approved'''
+
*[[Lasofoxifene (Fablyn)]]
 
*[[Lenalidomide (Revlimid)]]
 
*[[Lenalidomide (Revlimid)]]
 
*[[Lenvatinib (Lenvima)]]
 
*[[Lenvatinib (Lenvima)]]
−
*[[Letermovir (Prevymis)]]
 
 
*[[Letrozole (Femara)]]
 
*[[Letrozole (Femara)]]
 
*[[Leuprolide (Lupron)]]
 
*[[Leuprolide (Lupron)]]
 
*[[Levoleucovorin (Fusilev)]]
 
*[[Levoleucovorin (Fusilev)]]
−
*[[Lisocabtagene maraleucel (Breyanzi)]] '''FDA approved 2/5/2021'''
+
*[[Lifileuecel (Contego)]] '''FDA approved 2024-02-16'''
 +
*[[Lisocabtagene maraleucel (Breyanzi)]]
 
*[[Lobaplatin (D-19466)]]
 
*[[Lobaplatin (D-19466)]]
 
*[[Lomustine (CCNU)]]
 
*[[Lomustine (CCNU)]]
−
*[[Loncastuximab tesirine (Zynlonta)]] '''FDA approved 4/23/2021'''
+
*[[Loncastuximab tesirine (Zynlonta)]]
 
*[[Lorlatinib (Lorbrena)]]
 
*[[Lorlatinib (Lorbrena)]]
 
*[[Lurbinectedin (Zepzelca)]]
 
*[[Lurbinectedin (Zepzelca)]]
 
*[[Lutetium Lu 177 dotatate (Lutathera)]]
 
*[[Lutetium Lu 177 dotatate (Lutathera)]]
−
*[[Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)]] '''FDA approved 3/23/2022'''
+
*[[Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)]]
  
 
==M==
 
==M==
Line 265: Line 288:
 
*[[Margetuximab (Margenza)]]
 
*[[Margetuximab (Margenza)]]
 
*[[Mechlorethamine (Mustargen)]]
 
*[[Mechlorethamine (Mustargen)]]
−
*[[Medroxyprogesterone (MPA)]]
+
*[[Medroxyprogesterone acetate (MPA)]]
 
*[[Megestrol (Megace)]]
 
*[[Megestrol (Megace)]]
 
*[[Melphalan (Alkeran)]]
 
*[[Melphalan (Alkeran)]]
 +
*[[Melphalan for Injection-Hepatic Delivery System (Hepzato Kit)]] '''FDA approved on 2023-08-14'''
 
*[[Mepolizumab (Nucala)]]
 
*[[Mepolizumab (Nucala)]]
 
*[[Mercaptopurine (6-MP)]]
 
*[[Mercaptopurine (6-MP)]]
Line 275: Line 299:
 
*[[Midostaurin (Rydapt)]]
 
*[[Midostaurin (Rydapt)]]
 
*[[Mifamurtide (Mepact)]]
 
*[[Mifamurtide (Mepact)]]
−
*[[Mitomycin (Jelmyto)]]
+
*[[Miriplatin (Miripla)]]
 +
*[[Mirvetuximab soravtansine (Elahere)]]
 +
*[[Mitomycin pyelocalyceal (Jelmyto)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Mitomycin (Mutamycin)]]
 
*[[Mitotane (Lysodren)]]
 
*[[Mitotane (Lysodren)]]
 
*[[Mitoxantrone (Novantrone)]]
 
*[[Mitoxantrone (Novantrone)]]
−
*[[Mobocertinib (Exkivity)]] '''FDA approved on 9/15/2021'''
+
*[[Mobocertinib (Exkivity)]]
 
*[[Mogamulizumab (Poteligeo)]]
 
*[[Mogamulizumab (Poteligeo)]]
 +
*[[Momelotinib (Ojjaara)]] '''FDA approved 2023-09-15'''
 +
*[[Mosunetuzumab (Lunsumio)]]
 
*[[Moxetumomab pasudotox (Lumoxiti)]]
 
*[[Moxetumomab pasudotox (Lumoxiti)]]
  
 
==N==
 
==N==
−
 
+
*[[Nadofaragene firadenovec (Adstiladrin)]]
−
 
 
 
*[[Naxitamab (Danyelza)]]
 
*[[Naxitamab (Danyelza)]]
 
*[[Necitumumab (Portrazza)]]
 
*[[Necitumumab (Portrazza)]]
 
*[[Nedaplatin (Aqupla)]]
 
*[[Nedaplatin (Aqupla)]]
 
*[[Nelarabine (Arranon)]]
 
*[[Nelarabine (Arranon)]]
−
*[[NEOD001]]
 
 
*[[Neratinib (Nerlynx)]]
 
*[[Neratinib (Nerlynx)]]
 
*[[Nilotinib (Tasigna)]]
 
*[[Nilotinib (Tasigna)]]
Line 298: Line 324:
 
*[[Nintedanib (Vargatef)]]
 
*[[Nintedanib (Vargatef)]]
 
*[[Niraparib (Zejula)]]
 
*[[Niraparib (Zejula)]]
 +
*[[Niraparib and abiraterone (Akeega)]] '''FDA approved 2023-08-11'''
 +
*[[Nirogacestat (Ogsiveo)]] '''FDA approved 2023-11-27'''
 
*[[Nivolumab (Opdivo)]]
 
*[[Nivolumab (Opdivo)]]
−
*[[Nivolumab and relatlimab (Opdualag)]] '''FDA approved 3/18/2022'''
+
*[[Nivolumab and relatlimab (Opdualag)]]
−
*[[Nolatrexed (Thymitaq)]]
+
*[[Nogapendekin alfa inbakicept (Anktiva)]] '''FDA approved 2024-04-22'''
 
*[[Non-pegylated liposomal doxorubicin (Myocet)]]
 
*[[Non-pegylated liposomal doxorubicin (Myocet)]]
 
*[[Norethandrolone (Nilevar)]]
 
*[[Norethandrolone (Nilevar)]]
Line 312: Line 340:
 
*[[Ofatumumab (Arzerra)]]
 
*[[Ofatumumab (Arzerra)]]
 
*[[Olaparib (Lynparza)]]
 
*[[Olaparib (Lynparza)]]
 +
*[[Olutasidenib (Rezlidhia)]]
 +
*[[Olverembatinib (HQP-1351)]]
 
*[[Omacetaxine (Synribo)]]
 
*[[Omacetaxine (Synribo)]]
 
*[[Osimertinib (Tagrisso)]]
 
*[[Osimertinib (Tagrisso)]]
Line 322: Line 352:
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Paclitaxel, polymeric micelle-bound (Genexol-PM)]]
 
*[[Paclitaxel, polymeric micelle-bound (Genexol-PM)]]
−
*[[Pacritinib (Vonjo)]] '''FDA approved 3/1/2022'''
+
*[[Pacritinib (Vonjo)]]
 +
*[[Padeliporfin (Tookad)]]
 
*[[Palbociclib (Ibrance)]]
 
*[[Palbociclib (Ibrance)]]
 
*[[Panitumumab (Vectibix)]]
 
*[[Panitumumab (Vectibix)]]
Line 330: Line 361:
 
*[[Peginterferon alfa-2a (Pegasys)]]
 
*[[Peginterferon alfa-2a (Pegasys)]]
 
*[[Peginterferon alfa-2b (Sylatron)]]
 
*[[Peginterferon alfa-2b (Sylatron)]]
 +
*[[Pegylated liposomal doxorubicin (Doxil)]]
 
*[[Pembrolizumab (Keytruda)]]
 
*[[Pembrolizumab (Keytruda)]]
 
*[[Pemetrexed (Alimta)]]
 
*[[Pemetrexed (Alimta)]]
 
*[[Pemigatinib (Pemazyre)]]
 
*[[Pemigatinib (Pemazyre)]]
 +
*[[Penpulimab (Anniko)]]
 
*[[Pentostatin (Nipent)]]
 
*[[Pentostatin (Nipent)]]
 
*[[Pertuzumab (Perjeta)]]
 
*[[Pertuzumab (Perjeta)]]
−
*[[Pertuzumab & Trastuzumab hyaluronidase (Phesgo)]]
+
*[[Pertuzumab and Trastuzumab hyaluronidase (Phesgo)]]
 
*[[Pexidartinib (Turalio)]]
 
*[[Pexidartinib (Turalio)]]
 +
*[[Pipobroman (Vercyte)]]
 
*[[Pirarubicin (THP)]]
 
*[[Pirarubicin (THP)]]
 +
*[[Pirtobrutinib (Jaypirca)]] '''FDA approved 2023-01-27'''
 
*[[Pixantrone (Pixuvri)]]
 
*[[Pixantrone (Pixuvri)]]
 
*[[Polatuzumab vedotin (Polivy)]]
 
*[[Polatuzumab vedotin (Polivy)]]
Line 348: Line 383:
 
*[[Prednisolone (Millipred)]]
 
*[[Prednisolone (Millipred)]]
 
*[[Procarbazine (Matulane)]]
 
*[[Procarbazine (Matulane)]]
 +
*[[Pyrotinib (Irene)]]
 +
 +
==Q==
 +
*[[Quizartinib (Vanflyta)]]
  
 
==R==
 
==R==
−
 
+
*[[Racotumomab (Vaxira)]]
−
 
+
*[[Radium-223 (Xofigo)]]
−
*[[Radium Ra 223 (Xofigo)]]
 
 
*[[Radotinib (Supect)]]
 
*[[Radotinib (Supect)]]
 
*[[Raltitrexed (Tomudex)]]
 
*[[Raltitrexed (Tomudex)]]
Line 361: Line 399:
 
*[[Regorafenib (Stivarga)]]
 
*[[Regorafenib (Stivarga)]]
 
*[[Relugolix (Orgovyx)]]
 
*[[Relugolix (Orgovyx)]]
 +
*[[Repotrectinib (Augtyro)]] '''FDA approved 2023-11-15'''
 +
*[[Retifanlimab (Zynyz)]] '''FDA approved 2023-03-22'''
 
*[[Ribociclib (Kisqali)]]
 
*[[Ribociclib (Kisqali)]]
 
*[[Ripretinib (Qinlock)]]
 
*[[Ripretinib (Qinlock)]]
Line 367: Line 407:
 
**[[Rituximab-arrx (Riabni)]]
 
**[[Rituximab-arrx (Riabni)]]
 
**[[Rituximab-pvvr (Ruxience)]]
 
**[[Rituximab-pvvr (Ruxience)]]
−
**[[Rituximab (Blitzima)]]
+
**[[Rituximab-blit (Blitzima)]]
−
**[[Rituximab (Ritemvia)]]
+
**[[Rituximab-rite (Ritemvia)]]
−
**[[Rituximab (Rixathon)]]
+
**[[Rituximab-rixa (Rixathon)]]
−
**[[Rituximab (Riximyo)]]
+
**[[Rituximab-rixi (Riximyo)]]
−
*[[Rituximab and hyaluronidase human (Rituximab Hycela)]]
+
*[[Rituximab and hyaluronidase human (Rituxan Hycela)]]
 
*[[Romidepsin (Istodax)]]
 
*[[Romidepsin (Istodax)]]
 +
*[[Ropeginterferon alfa-2b (Besremi)]]
 
*[[Rucaparib (Rubraca)]]
 
*[[Rucaparib (Rubraca)]]
 
*[[Ruxolitinib (Jakafi)]]
 
*[[Ruxolitinib (Jakafi)]]
Line 384: Line 425:
 
*[[Selpercatinib (Retevmo)]]
 
*[[Selpercatinib (Retevmo)]]
 
*[[Selumetinib (Koselugo)]]
 
*[[Selumetinib (Koselugo)]]
 +
*[[Serplulimab (Hansizhuang)]]
 
*[[Sintilimab (Tyvyt)]]
 
*[[Sintilimab (Tyvyt)]]
 
*[[Sipuleucel-T (Provenge)]]
 
*[[Sipuleucel-T (Provenge)]]
−
*[[Sirolimus protein-bound particles (Fyarro)]] '''FDA approved 11/22/2021'''
+
*[[Sirolimus protein-bound particles (Fyarro)]]
 
*[[Sonidegib (Odomzo)]]
 
*[[Sonidegib (Odomzo)]]
 
*[[Sorafenib (Nexavar)]]
 
*[[Sorafenib (Nexavar)]]
−
*[[Sotorasib (Lumakras)]] '''FDA approved 5/28/2021'''
+
*[[Sotorasib (Lumakras)]]
 
*[[Stilbamidine]]
 
*[[Stilbamidine]]
 
*[[Streptozocin (Zanosar)]]
 
*[[Streptozocin (Zanosar)]]
 
*[[Strontium-89 (Metastron)]]
 
*[[Strontium-89 (Metastron)]]
 +
*[[Sugemalimab (Cejemly)]]
 
*[[Sunitinib (Sutent)]]
 
*[[Sunitinib (Sutent)]]
 
*[[Suramin (Antrypol)]]
 
*[[Suramin (Antrypol)]]
  
 
==T==
 
==T==
−
 
+
*[[Tabelecleucel (Ebvallo)]]
 
*[[Tafasitamab (Monjuvi)]]
 
*[[Tafasitamab (Monjuvi)]]
 
*[[Tagraxofusp (Elzonris)]]
 
*[[Tagraxofusp (Elzonris)]]
 
*[[Talazoparib (Talzenna)]]
 
*[[Talazoparib (Talzenna)]]
 
*[[Talimogene laherparepvec (Imlygic)]]
 
*[[Talimogene laherparepvec (Imlygic)]]
 +
*[[Taloporfin (Laserphyrin)]]
 +
*[[Talquetamab (Talvey)]] '''FDA approved 2023-08-09'''
 +
*[[Tamibarotene (Amnoid)]]
 
*[[Tamoxifen (Nolvadex)]]
 
*[[Tamoxifen (Nolvadex)]]
 +
*[[Tarlatamab (Imdelltra)]] '''FDA approved 2024-05-16'''
 
*[[Tasonermin (Beromun)]]
 
*[[Tasonermin (Beromun)]]
 
*[[Tazemetostat (Tazverik)]]
 
*[[Tazemetostat (Tazverik)]]
 +
*[[Tebentafusp (Kimmtrak)]]
 +
*[[Teclistamab (Tecvayli)]]
 
*[[Tegafur and uracil (UFT)]]
 
*[[Tegafur and uracil (UFT)]]
 
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]]
 
*[[Tegafur, gimeracil, oteracil (Teysuno, S-1)]]
−
*[[Telotristat (Xermelo)]]
+
*[[Temoporfin (Foscan)]]
 
*[[Temozolomide (Temodar)]]
 
*[[Temozolomide (Temodar)]]
 
*[[Temsirolimus (Torisel)]]
 
*[[Temsirolimus (Torisel)]]
 
*[[Teniposide (Vumon)]]
 
*[[Teniposide (Vumon)]]
−
*[[Tepotinib (Tepmetko)]] '''FDA approved 2/3/2021'''
+
*[[Tepotinib (Tepmetko)]]
 
*[[Thalidomide (Thalomid)]]
 
*[[Thalidomide (Thalomid)]]
 
*[[Thioguanine (Tabloid)]]
 
*[[Thioguanine (Tabloid)]]
 
*[[Thiotepa (Tepadina)]]
 
*[[Thiotepa (Tepadina)]]
 
*[[Thiotepa (Thioplex)]]
 
*[[Thiotepa (Thioplex)]]
 +
*[[Tirabrutinib (Velexbru)]]
 
*[[Tisagenlecleucel (Kymriah)]]
 
*[[Tisagenlecleucel (Kymriah)]]
−
*[[Tisotumab vedotin (Tivdak)]] '''FDA approved 9/20/2021'''
+
*[[Tisotumab vedotin (Tivdak)]]
 
*[[Topotecan (Hycamtin)]]
 
*[[Topotecan (Hycamtin)]]
 
*[[Toremifene (Fareston)]]
 
*[[Toremifene (Fareston)]]
−
*[[Toripalimab (Tuoyi)]]
+
*[[Toripalimab (Loqtorzi)]] '''FDA approved 2023-10-27'''
 
*[[Tositumomab and I-131 (Bexxar)]]
 
*[[Tositumomab and I-131 (Bexxar)]]
 +
*[[Tovorafenib (Ojemda)]] '''FDA approved 2024-04-23'''
 
*[[Trabectedin (Yondelis)]]
 
*[[Trabectedin (Yondelis)]]
 
*[[Trametinib (Mekinist)]]
 
*[[Trametinib (Mekinist)]]
Line 428: Line 479:
 
**[[Trastuzumab-dkst (Ogivri)]]
 
**[[Trastuzumab-dkst (Ogivri)]]
 
**[[Trastuzumab-dttb (Ontruzant)]]
 
**[[Trastuzumab-dttb (Ontruzant)]]
 +
**[[Trastuzumab-herw (Herwenda)]]
 
**[[Trastuzumab-pkrb (Herzuma)]]
 
**[[Trastuzumab-pkrb (Herzuma)]]
 
**[[Trastuzumab-qyyp (Trazimera)]]
 
**[[Trastuzumab-qyyp (Trazimera)]]
−
**[[Trastuzumab (Zercepac)]]
+
**[[Trastuzumab-strf (Hercessi)]] '''FDA approved 2024-04-29'''
 +
**[[Trastuzumab-zerc (Zercepac)]]
 
*[[Trastuzumab and hyaluronidase (Herceptin Hylecta)]]
 
*[[Trastuzumab and hyaluronidase (Herceptin Hylecta)]]
 +
*[[Trastuzumab deruxtecan (Enhertu)]]
 +
*[[Trastuzumab emtansine (Kadcyla)]]
 +
*[[Tremelimumab (Imjudo)]]
 
*[[Treosulfan (Ovastat)]]
 
*[[Treosulfan (Ovastat)]]
 
*[[Trifluridine and tipiracil (Lonsurf)]]
 
*[[Trifluridine and tipiracil (Lonsurf)]]
Line 437: Line 493:
 
*[[Trimetrexate (Neutrexin)]]
 
*[[Trimetrexate (Neutrexin)]]
 
*[[Triptorelin (Trelstar LA)]]
 
*[[Triptorelin (Trelstar LA)]]
 +
*[[Trofosfamide (Ixoten)]]
 
*[[Tucatinib (Tukysa)]]
 
*[[Tucatinib (Tukysa)]]
  
 
==U==
 
==U==
−
 
+
*[[Ublituximab (Briumvi)]] '''FDA approved 2023-01-06'''
−
*[[Umbralisib (Ukoniq)]] '''FDA approved 2/5/2021'''
 
−
 
 
 
==V==
 
==V==
−
 
+
*[[Valemetostat (Ezharmia)]]
 
*[[Valrubicin (Valstar)]]
 
*[[Valrubicin (Valstar)]]
 
*[[Vandetanib (Caprelsa)]]
 
*[[Vandetanib (Caprelsa)]]
Line 451: Line 506:
 
*[[Vinblastine (Velban)]]
 
*[[Vinblastine (Velban)]]
 
*[[Vincristine (Oncovin)]]
 
*[[Vincristine (Oncovin)]]
−
*[[Vincristine liposomal (Marqibo)]]
 
 
*[[Vindesine (Eldisine)]]
 
*[[Vindesine (Eldisine)]]
 
*[[Vinflunine (Javlor)]]
 
*[[Vinflunine (Javlor)]]
Line 462: Line 516:
  
 
*[[Zanubrutinib (Brukinsa)]]
 
*[[Zanubrutinib (Brukinsa)]]
 +
*[[Zimberelimab (Yu Duo)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
 +
**[[Aflibercept-jbvf (Yesafili)]] '''FDA approved 2024-05'''
 +
**[[Aflibercept-yszy (Opuviz)]] '''FDA approved 2024-05'''
  
 
=Discontinued antineoplastics=
 
=Discontinued antineoplastics=
Line 481: Line 538:
  
 
*[[Edrecolomab (Panorex)]]
 
*[[Edrecolomab (Panorex)]]
 +
*[[Ethinylestradiol]]
  
 
==F==
 
==F==
Line 501: Line 559:
  
 
==P==
 
==P==
−
 
+
*[[Paclitaxel poliglumex (Opaxio)]]
 
*[[Plicamycin (Mithracin)]]
 
*[[Plicamycin (Mithracin)]]
 +
*[[Polyestradiol phosphate (Estradurin)]]
  
 
==S==
 
==S==
Line 509: Line 568:
  
 
==T==
 
==T==
−
 
 
*[[Testolactone (Teslac)]]
 
*[[Testolactone (Teslac)]]
 +
*[[Triethylenemelamine (Tretamine)]]
  
 
==U==
 
==U==
−
 
+
*[[Umbralisib (Ukoniq)]]
 
*[[Uracil mustard]]
 
*[[Uracil mustard]]
 
*[[Urethane]]
 
*[[Urethane]]
 +
 +
==V==
 +
*[[Vincristine liposomal (Marqibo)]]
  
 
=Investigational antineoplastics=
 
=Investigational antineoplastics=
Line 523: Line 585:
 
*[[Abexinostat (PCI-24781)]]
 
*[[Abexinostat (PCI-24781)]]
 
*[[Actinium Ac 225 lintuzumab (Actimab-A)]]
 
*[[Actinium Ac 225 lintuzumab (Actimab-A)]]
−
*[[Adagrasib (MRTX849)]]
 
 
*[[Adavosertib (MK-1775)]]
 
*[[Adavosertib (MK-1775)]]
 
*[[Adebrelimab (SHR-1316)]]
 
*[[Adebrelimab (SHR-1316)]]
−
*[[Adenovirus-interferon-γ (TG1042)]]
+
*[[Adenovirus-interferon-γ (TG-1042)]]
−
*[[Afuresertib (GSK2110183)]]
+
*[[Afamitresgene Autoleucel (ADP-A2M4)]]
−
*[[Alisertib (MLN8237)]]
+
*[[Afuresertib (GSK-2110183)]]
 +
*[[Agatolimod (PF-3512676)]]
 +
*[[Alisertib (MLN-8237)]]
 
*[[Amatuximab (MORAb-009)]]
 
*[[Amatuximab (MORAb-009)]]
−
*[[AMG 330]]
 
 
*[[Amonafide (Quinamed)]]
 
*[[Amonafide (Quinamed)]]
−
*[[Apocept (APG101)]]
+
*[[Apocept (APG-101)]]
−
*[[Astuprotimut-R (GSK1572932A)]]
+
*[[Astuprotimut-R (GSK-1572932A)]]
  
 
==B==
 
==B==
  
−
*[[Barasertib (AZD1152)]]
+
*[[Barasertib (AZD-1152)]]
−
*[[Bavituximab (PGN401)]]
+
*[[Bavituximab (PGN-401)]]
 +
*[[Befotertinib (D-0316)]]
 
*[[Belagenpumatucel-L (Lucanix)]]
 
*[[Belagenpumatucel-L (Lucanix)]]
−
*[[BHQ880]]
+
*[[BE-CAR7]]
 +
*[[BHQ-880]]
 +
*[[Birtamimab (NEOD-001)]]
 
*[[BL22 immunotoxin (CAT-3888)]]
 
*[[BL22 immunotoxin (CAT-3888)]]
−
*[[Buparlisib (BKM120)]]
+
*[[Buparlisib (BKM-120)]]
  
 
==C==
 
==C==
−
 
+
*[[CARv3-TEAM-E T-cells]]
−
*[[Capivasertib (AZD5363)]]
 
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Catumaxomab (Removab)]] '''in US clinical trials'''
 
*[[Cediranib (Recentin)]]
 
*[[Cediranib (Recentin)]]
 
*[[Cixutumumab (IMC-A12)]]
 
*[[Cixutumumab (IMC-A12)]]
−
*[[Coltuximab ravtansine (CoR, SAR3419)]]
+
*[[Coltuximab ravtansine (SAR-3419)]]
 
*[[Crenolanib (CP-868,596)]]
 
*[[Crenolanib (CP-868,596)]]
 
*[[Custirsen (OGX-011)]]
 
*[[Custirsen (OGX-011)]]
Line 556: Line 620:
 
==D==
 
==D==
  
−
*[[Dalpiciclib (SHR6390)]]
+
*[[Dalpiciclib (SHR-6390)]]
 +
*[[Danicopan (ALXN-2040)]]
 +
*[[Datopotamab deruxtecan (DS-1062)]]
 
*[[Denintuzumab mafodotin (SGN-CD19A)]]
 
*[[Denintuzumab mafodotin (SGN-CD19A)]]
−
*[[Dinaciclib (SCH 727965)]]
+
*[[Dinaciclib (SCH-727965)]]
−
*[[Discodermolide (XAA296)]]
+
*[[Divarasib (GDC-6036)]]
−
*[[DMUC5754A]]
+
*[[Discodermolide (XAA-296)]]
 +
*[[DMUC-5754A]]
 
*[[Dovitinib (TKI-258)]]
 
*[[Dovitinib (TKI-258)]]
  
 
==E==
 
==E==
−
 
 
*[[Emepepimut-S (Stimuvax)]]
 
*[[Emepepimut-S (Stimuvax)]]
−
*[[Ensartinib (X-396)]]
+
*[[Eluvixtamab (AMG-330)]]
 
*[[Entinostat (SNDX-275)]]
 
*[[Entinostat (SNDX-275)]]
 
*[[Entospletinib (GS-9973)]]
 
*[[Entospletinib (GS-9973)]]
−
*[[Epcoritamab (GEN-3013)]]
+
*[[Envonalkib (TQ-B3139)]]
 
*[[Epratuzumab (LymphoCide)]]
 
*[[Epratuzumab (LymphoCide)]]
 
*[[Etirinotecan pegol (NKTR-102)]]
 
*[[Etirinotecan pegol (NKTR-102)]]
  
 
==F==
 
==F==
−
 
+
*[[Farletuzumab (MORAb-003)]]
 +
*[[Figitumumab (CP-751,871)]]
 
*[[Filanesib (ARRY-520)]]
 
*[[Filanesib (ARRY-520)]]
−
*[[Flumatinib (HH-GV-678)]]
 
−
*[[Fruquintinib (HMPL-013)]]
 
−
*[[Futibatinib (TAS-120)]]
 
  
 
==G==
 
==G==
−
 
 
*[[G207]]
 
*[[G207]]
 
*[[Galeterone (TOK-001)]]
 
*[[Galeterone (TOK-001)]]
−
*[[Galunisertib (LY2157299)]]
+
*[[Galunisertib (LY-2157299)]]
 
*[[Ganetespib (STA-9090)]]
 
*[[Ganetespib (STA-9090)]]
−
*[[Ganitumab (AMG 479)]]
+
*[[Ganitumab (AMG-479)]]
−
*[[Gemcitabine elaidate (CP-4126, CO-101)]]
+
*[[GD2-CART01]]
−
*[[Glembatumumab vedotin (CDX-011)]]]
+
*[[Gemcitabine elaidate (CP-4126)]]
 +
*[[Glembatumumab vedotin (CDX-011)]]
 
*[[Guadecitabine (SGI-110)]]
 
*[[Guadecitabine (SGI-110)]]
  
Line 598: Line 662:
 
==I==
 
==I==
  
−
*[[Idasanutlin (RG7388)]]
+
*[[Idasanutlin (RG-7388)]]
−
*[[IMA901]]
+
*[[IMA-901]]
−
*[[Imetelstat (GRN163L)]]
+
*[[Indatuximab ravtansine (BT-062)]]
−
*[[Indatuximab ravtansine (BT062)]]
 
 
*[[Ipatasertib (GDC-0068)]]
 
*[[Ipatasertib (GDC-0068)]]
−
*[[IPH 2101]]
+
*[[IPH-2101]]
  
 
==J==
 
==J==
Line 617: Line 680:
 
*[[Lorvotuzumab mertansine (BB-10901)]]
 
*[[Lorvotuzumab mertansine (BB-10901)]]
 
*[[Lutetium-177-PSMA-617]]
 
*[[Lutetium-177-PSMA-617]]
−
*[[LY3023414]]
+
*[[LY-3023414]]
  
 
==M==
 
==M==
 +
*[[Magrolimab (Hu5F9-G4)]]
 +
*[[Mapatumumab (HGS-ETR1)]]
 +
*[[Masitinib (AB-1010)]]
 +
*[[MCARH-109]]
 +
*[[Mezigdomide (BMS-986348)]]
 +
*[[Milataxel (TL-139)]]
 +
*[[MK-2206]]
 +
*[[Mocetinostat (MGCD-0103)]]
 +
*[[Motesanib (AMG-706)]]
  
−
*[[Mapatumumab (HGS-ETR1)]]
+
==N==
−
*[[Masitinib (AB1010)]]
+
*[[Nolatrexed (Thymitaq)]]
−
*[[Milataxel (TL139)]]
 
−
*[[Mirvetuximab soravtansine (IMGN853)]]
 
−
*[[MK2206]]
 
−
*[[Mocetinostat (MGCD0103)]]
 
−
*[[Momelotinib (CYT387)]]
 
−
*[[MOR208]]
 
−
*[[Motesanib (AMG 706)]]
 
  
 
==O==
 
==O==
−
 
+
*[[Oblimersen (Genasense)]]
 
*[[Olaptesed pegol (NOX-A12)]]
 
*[[Olaptesed pegol (NOX-A12)]]
 
*[[Onartuzumab (MetMAb)]]
 
*[[Onartuzumab (MetMAb)]]
−
*[[Oprozomib (ONX 0912)]]
+
*[[Oprozomib (ONX-0912)]]
 
*[[Orteronel (TAK-700)]]
 
*[[Orteronel (TAK-700)]]
−
*[[Osocimab (BAY 1213790)]]
+
*[[Osocimab (BAY-1213790)]]
 
*[[Otlertuzumab (TRU-016)]]
 
*[[Otlertuzumab (TRU-016)]]
  
 
==P==
 
==P==
−
 
+
*[[Patritumab deruxtecan (U3-1402)]]
 
*[[Pentraxin 2 (PRM-151)]]
 
*[[Pentraxin 2 (PRM-151)]]
 
*[[Perifosine (KRX-0401)]]
 
*[[Perifosine (KRX-0401)]]
Line 647: Line 712:
 
*[[Pictilisib (GDC-0941)]]
 
*[[Pictilisib (GDC-0941)]]
 
*[[Pidilizumab (CT-011)]]
 
*[[Pidilizumab (CT-011)]]
−
*[[Pinatuzumab vedotin (DCDT2980S)]]
+
*[[Pimitespib (TAS-116)]]
−
*[[Pirtobrutinib (LOXO-305)]]
+
*[[Pinatuzumab vedotin (DCDT-2980S)]]
 
*[[Plinabulin (NPI-2358)]]
 
*[[Plinabulin (NPI-2358)]]
−
*[[Pracinostat (SB939)]]
+
*[[Pracinostat (SB-939)]]
  
 
==Q==
 
==Q==
Line 656: Line 721:
  
 
==R==
 
==R==
−
 
+
*[[Rebimastat (BMS-275291)]]
−
*[[Refametinib (BAY 869766)]]
+
*[[Refametinib (BAY-869766)]]
 
*[[Reovirus (Reolysin)]]
 
*[[Reovirus (Reolysin)]]
 
*[[Retaspimycin (IPI-504)]]
 
*[[Retaspimycin (IPI-504)]]
−
*[[Ricolinostat (ACY-1215, Rocilinostat)]]
+
*[[Revumenib (SNDX-5613)]]
−
*[[Ridaforolimus (AP23573)]]
+
*[[Rezvilutamide (SHR-3680)]]
−
*[[Rilotumumab (AMG 102)]]
+
*[[Ricolinostat (ACY-1215)]]
 +
*[[Ridaforolimus (AP-23573)]]
 +
*[[Rilotumumab (AMG-102)]]
 +
*[[Ripertamab (SCT-400)]]
 
*[[Rociletinib (CO-1686)]]
 
*[[Rociletinib (CO-1686)]]
−
*[[Ropeginterferon alfa-2b (AOP2014)]]
 
  
 
==S==
 
==S==
  
 
*[[Sapacitabine (CS-682)]]
 
*[[Sapacitabine (CS-682)]]
−
*[[Sapanisertib (MLN0128)]]
+
*[[Sapanisertib (MLN-0128)]]
−
*[[Seliciclib (CYC202)]]
+
*[[Seliciclib (CYC-202)]]
−
*[[Semuloparin (AVE5026)]]
+
*[[Semuloparin (AVE-5026)]]
 
*[[Spebrutinib (CC-292)]]
 
*[[Spebrutinib (CC-292)]]
 
*[[Surufatinib (HMPL-012)]]
 
*[[Surufatinib (HMPL-012)]]
−
*[[Sutimlimab (BIVV009)]]
 
  
 
==T==
 
==T==
  
−
*[[Tabalumab (LY2127399)]]
+
*[[Tabalumab (LY-2127399)]]
−
*[[Tamibarotene (Amnoid)]]
 
 
*[[Tasadenoturev (DNX-2401)]]
 
*[[Tasadenoturev (DNX-2401)]]
−
*[[Tebentafusp (IMCgp100)]]
+
*[[Telisotuzumab vedotin (ABBV-399)]]
−
*[[Teclistamab (JNJ 64007957)]]
+
*[[Tertomotide (GV-1001)]]
 
*[[Tesetaxel (DJ-927)]]
 
*[[Tesetaxel (DJ-927)]]
−
*[[Tesevatinib (XL647)]]
+
*[[Tesevatinib (XL-647)]]
 
*[[Tigatuzumab (CS-1008)]]
 
*[[Tigatuzumab (CS-1008)]]
 
*[[Tipifarnib (Zarnestra)]]
 
*[[Tipifarnib (Zarnestra)]]
−
*[[Tirabrutinib (GS-4059)]]
+
*[[Tirapazamine (Tirazone)]]
−
*[[Tislelizumab (BGB-A317)]]
+
*[[Tislelizumab (Baizean)]]
−
*[[Tivantinib (ARQ 197)]]
+
*[[Tivantinib (ARQ-197)]]
 
*[[Tivozanib (AV-951)]]
 
*[[Tivozanib (AV-951)]]
 
*[[Tosedostat (CHR-2797)]]
 
*[[Tosedostat (CHR-2797)]]
−
*[[Trebananib (AMG 386)]]
+
*[[Trebananib (AMG-386)]]
−
*[[Tremelimumab (ticilimumab)]]
+
*[[Tusamitamab ravtansine (SAR-408701)]]
  
 
==U==
 
==U==
−
 
−
*[[Ublituximab (TG-1101)]]
 
 
*[[UCART19]]
 
*[[UCART19]]
  
Line 703: Line 766:
  
 
*[[Vadastuximab talirine (SGN-CD33A)]]
 
*[[Vadastuximab talirine (SGN-CD33A)]]
 +
*[[Vadimezan (AS-A404)]]
 
*[[Varlilumab (CDX-1127)]]
 
*[[Varlilumab (CDX-1127)]]
 
*[[Veliparib (ABT-888)]]
 
*[[Veliparib (ABT-888)]]
 
*[[Veltuzumab (hA20)]]
 
*[[Veltuzumab (hA20)]]
−
*[[Volasertib (BI 6727)]]
+
*[[Volasertib (BI-6727)]]
−
*[[Vosaroxin (SNS 595)]]
+
*[[Vorasidenib (AG-881)]]
−
*[[Voxtalisib (XL765)]]
+
*[[Vorolanib (CM-082)]]
 +
*[[Vosaroxin (SNS-595)]]
 +
*[[Voxtalisib (XL-765)]]
  
 
==Z==
 
==Z==
  
 
*[[Zandelisib (ME-401)]]
 
*[[Zandelisib (ME-401)]]
 +
*[[Zolbetuximab (IMAB-362)]]
  
 
=Supportive and other medications=
 
=Supportive and other medications=
−
 
+
''This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.''
 
==A==
 
==A==
  
Line 722: Line 789:
 
*[[Acetazolamide (Diamox)]]
 
*[[Acetazolamide (Diamox)]]
 
*[[Acyclovir (Zovirax)]]
 
*[[Acyclovir (Zovirax)]]
 +
*[[ADAMTS13, recombinant (Adzynma)]]
 
*[[Alendronate (Fosamax)]]
 
*[[Alendronate (Fosamax)]]
 
*[[Alizapride (Litican)]]
 
*[[Alizapride (Litican)]]
Line 729: Line 797:
 
*[[Amoxicillin]]
 
*[[Amoxicillin]]
 
*[[Anagrelide (Agrylin)]]
 
*[[Anagrelide (Agrylin)]]
 +
*[[Andexanet alfa (Andexxa)]]
 
*[[Anti-inhibitor coagulant complex (FEIBA NF)]]
 
*[[Anti-inhibitor coagulant complex (FEIBA NF)]]
 
*[[Antithrombin III (human and recombinant)]]
 
*[[Antithrombin III (human and recombinant)]]
Line 747: Line 816:
  
 
==B==
 
==B==
−
*[[Betibeglogene autotemcel (Zynteglo)]] '''FDA approved 8/17/2022'''
+
*[[Betibeglogene autotemcel (Zynteglo)]]
 
*[[Betrixaban (Bevyxxa)]]
 
*[[Betrixaban (Bevyxxa)]]
 
*[[Bismuth subsalicylate (Pepto-Bismol)]]
 
*[[Bismuth subsalicylate (Pepto-Bismol)]]
Line 756: Line 825:
 
*[[Cangrelor (Kengreal)]]
 
*[[Cangrelor (Kengreal)]]
 
*[[Calcium phosphate rinse (Caphosol)]]
 
*[[Calcium phosphate rinse (Caphosol)]]
 +
*[[Caspofungin (Cancidas)]]
 
*[[Cetirizine (Zyrtec)]]
 
*[[Cetirizine (Zyrtec)]]
 
*[[Chlorpheniramine (Chlor-Trimeton)]]
 
*[[Chlorpheniramine (Chlor-Trimeton)]]
Line 765: Line 835:
 
*[[Clodronate (Bonefos)]]
 
*[[Clodronate (Bonefos)]]
 
*[[Clopidogrel (Plavix)]]
 
*[[Clopidogrel (Plavix)]]
 +
*[[CM-313]]
 +
*[[Concizumab (Alhemo)]]
 
*[[Crizanlizumab (Adakveo)]]
 
*[[Crizanlizumab (Adakveo)]]
 
*[[Cyanocobalamin (Vitamin B12)]]
 
*[[Cyanocobalamin (Vitamin B12)]]
Line 783: Line 855:
 
*[[Defibrotide (Defitelio)]]
 
*[[Defibrotide (Defitelio)]]
 
*[[Denosumab (Xgeva)]]
 
*[[Denosumab (Xgeva)]]
 +
**[[Denosumab-bddz (Wyost)]]
 
*[[Desmopressin (DDAVP)]]
 
*[[Desmopressin (DDAVP)]]
 
*[[Dexchlorpheniramine (Polaramine)]]
 
*[[Dexchlorpheniramine (Polaramine)]]
Line 795: Line 868:
  
 
==E==
 
==E==
−
 
 
*[[Eculizumab (Soliris)]]
 
*[[Eculizumab (Soliris)]]
 +
**[[Eculizumab-beke (Bekemv)]]
 +
**[[Eculizumab-epys (Epysqli)]]
 
*[[Edoxaban (Savaysa)]]
 
*[[Edoxaban (Savaysa)]]
 +
*[[Efanesoctocog alfa (Altuviiio)]]
 +
*[[Eflapegrastim (Rolvedon)]]
 
*[[Eltrombopag (Promacta)]]
 
*[[Eltrombopag (Promacta)]]
−
*[[Emicizumab-kxwh (Hemlibra)]]
+
*[[Emicizumab (Hemlibra)]]
 
*[[Enoxaparin (Lovenox)]]
 
*[[Enoxaparin (Lovenox)]]
−
**[[Enoxaparin (Inhixa)]]
+
**[[Enoxaparin-inhi (Inhixa)]]
 
*[[Epoetin alfa (Procrit)]]
 
*[[Epoetin alfa (Procrit)]]
 
**[[Epoetin alfa-epbx (Retacrit)]]
 
**[[Epoetin alfa-epbx (Retacrit)]]
−
**[[Epoetin alfa (Abseamed)]]
+
**[[Epoetin alfa-abse (Abseamed)]]
−
**[[Epoetin alfa (Binocrit)]]
+
**[[Epoetin alfa-bino (Binocrit)]]
−
**[[Epoetin alfa (Epoetin Alfa Hexal)]]
+
**[[Epoetin alfa-hexa (Epoetin Alfa Hexal)]]
 +
*[[Epoetin theta (Biopoin)]]
 
*[[Epoetin zeta (Eprex)]]
 
*[[Epoetin zeta (Eprex)]]
−
**[[Epoetin zeta (Silapo)]]
+
**[[Epoetin zeta-reta (Retacrit)]]
 +
**[[Epoetin zeta-sila (Silapo)]]
 
*[[Eptifibatide (Integrilin)]]
 
*[[Eptifibatide (Integrilin)]]
 +
*[[Etranacogene dezaparvovec (Hemgenix)]]
 +
*[[Exagamglogene autotemcel (Casgevy)]] '''FDA approved on 2023-12-08'''
  
 
==F==
 
==F==
Line 820: Line 900:
 
*[[Factor IX, recombinant, Fc fusion protein (Alprolix)]]
 
*[[Factor IX, recombinant, Fc fusion protein (Alprolix)]]
 
*[[Factor X, human (Coagadex)]]
 
*[[Factor X, human (Coagadex)]]
−
*[[Factor Xa, recombinant, inactivated-zhzo (Andexxa)]]
 
 
*[[Factor XIII concentrate, human (Corifact)]]
 
*[[Factor XIII concentrate, human (Corifact)]]
 
*[[Famciclovir (Famvir)]]
 
*[[Famciclovir (Famvir)]]
 
*[[Famotidine (Pepcid)]]
 
*[[Famotidine (Pepcid)]]
 
*[[Ferric carboxymaltose (Injectafer)]]
 
*[[Ferric carboxymaltose (Injectafer)]]
 +
*[[Ferric derisomaltose (Monoferric)]]
 
*[[Ferric gluconate (Ferrlecit)]]
 
*[[Ferric gluconate (Ferrlecit)]]
 
*[[Ferrous sulfate (Feosol)]]
 
*[[Ferrous sulfate (Feosol)]]
Line 831: Line 911:
 
*[[Filgrastim (Neupogen)]]
 
*[[Filgrastim (Neupogen)]]
 
**[[Filgrastim-aafi (Nivestym)]]
 
**[[Filgrastim-aafi (Nivestym)]]
 +
**[[Filgrastim-ayow (Releuko)]]
 
**[[Filgrastim-sndz (Zarxio)]]
 
**[[Filgrastim-sndz (Zarxio)]]
−
**[[Filgrastim (Accofil)]]
+
**[[Filgrastim-acco (Accofil)]]
−
**[[Filgrastim (Filgrastim Hexal)]]
+
**[[Filgrastim-hexa (Filgrastim Hexal)]]
−
**[[Filgrastim (Grastofil)]]
+
**[[Filgrastim-gras (Grastofil)]]
−
**[[Filgrastim (Ratiograstim)]]
+
**[[Filgrastim-rati (Ratiograstim)]]
−
**[[Filgrastim (Tevagrastim)]]
+
**[[Filgrastim-teva (Tevagrastim)]]
 
*[[Finasteride (Proscar)]]
 
*[[Finasteride (Proscar)]]
 +
*[[Fitusiran (ALN-AT3SC)]]
 
*[[Fluconazole (Diflucan)]]
 
*[[Fluconazole (Diflucan)]]
 
*[[Folic acid (Folate)]]
 
*[[Folic acid (Folate)]]
 
*[[Fondaparinux (Arixtra)]]
 
*[[Fondaparinux (Arixtra)]]
 
*[[Fosaprepitant (Emend for Injection)]]
 
*[[Fosaprepitant (Emend for Injection)]]
 +
*[[Fosnetupitant (Arokaris)]]
 
*[[Furosemide (Lasix)]]
 
*[[Furosemide (Lasix)]]
  
Line 847: Line 930:
  
 
*[[Glucarpidase (Voraxaze)]]
 
*[[Glucarpidase (Voraxaze)]]
−
*[[Granisetron (Kytril)]]
+
*[[Granisetron]]
−
*[[Granisetron (Sancuso)]]
 
−
*[[Granisetron (Sustol)]]
 
  
 
==H==
 
==H==
Line 861: Line 942:
 
*[[Idarucizumab (Praxbind)]]
 
*[[Idarucizumab (Praxbind)]]
 
*[[Indomethacin (Indocin)]]
 
*[[Indomethacin (Indocin)]]
 +
*[[Iptacopan (Fabhalta)]] '''FDA approved 2023-12-05'''
 
*[[Iron dextran (INFeD)]]
 
*[[Iron dextran (INFeD)]]
 
*[[Iron sucrose (Venofer)]]
 
*[[Iron sucrose (Venofer)]]
Line 872: Line 954:
 
*[[Lenograstim (Granocyte)]]
 
*[[Lenograstim (Granocyte)]]
 
*[[Lepirudin (Refludan)]] '''discontinued'''
 
*[[Lepirudin (Refludan)]] '''discontinued'''
 +
*[[Letermovir (Prevymis)]]
 
*[[Levofloxacin (Levaquin)]]
 
*[[Levofloxacin (Levaquin)]]
 
*[[L-glutamine (Endari)]]
 
*[[L-glutamine (Endari)]]
−
*[[Lipefilgrastim (XM22)]] '''in clinical trials'''
+
*[[Lipefilgrastim (Lonquex)]]
 
*[[Loperamide (Imodium)]]
 
*[[Loperamide (Imodium)]]
 
*[[Lorazepam (Ativan)]]
 
*[[Lorazepam (Ativan)]]
 +
*[[Lovotibeglogene autotemcel (Lyfgenia)]] '''FDA approved on 2023-12-08'''
 
*[[Luspatercept (Reblozyl)]]
 
*[[Luspatercept (Reblozyl)]]
 
*[[Lusutrombopag (Mulpleta)]]
 
*[[Lusutrombopag (Mulpleta)]]
Line 888: Line 972:
 
*[[Methyltesterone (Android)]]
 
*[[Methyltesterone (Android)]]
 
*[[Metoclopramide (Reglan)]]
 
*[[Metoclopramide (Reglan)]]
−
*[[Mitapivat (AG-348)]] '''in clinical trials'''
+
*[[Mitapivat (Pyrukynd)]]
 +
*[[Motixafortide (Aphexda)]] '''FDA approved 2023-09'''
 
*[[Mycophenolate mofetil (CellCept)]]
 
*[[Mycophenolate mofetil (CellCept)]]
  
Line 896: Line 981:
 
*[[Nabilone (Cesamet)]]
 
*[[Nabilone (Cesamet)]]
 
*[[Netupitant and palonosetron (Akynzeo)]]
 
*[[Netupitant and palonosetron (Akynzeo)]]
 +
*[[Nonacog beta pegol (Refixia)]]
  
 
==O==
 
==O==
Line 901: Line 987:
 
*[[Olanzapine (Zyprexa)]]
 
*[[Olanzapine (Zyprexa)]]
 
*[[Omeprazole (Prilosec)]]
 
*[[Omeprazole (Prilosec)]]
 +
*[[Omidubicel (Omisirge)]] '''FDA approved 2023-04-17'''
 
*[[Ondansetron (Zofran)]]
 
*[[Ondansetron (Zofran)]]
 
*[[Oprelvekin (Neumega)]]
 
*[[Oprelvekin (Neumega)]]
Line 915: Line 1,002:
 
**[[Pegfilgrastim-bmez (Ziextenzo)]]
 
**[[Pegfilgrastim-bmez (Ziextenzo)]]
 
**[[Pegfilgrastim-cbqv (Udenyca)]]
 
**[[Pegfilgrastim-cbqv (Udenyca)]]
 +
**[[Pegfilgrastim-fpgk (Stimufend)]]
 
**[[Pegfilgrastim-jmdb (Fulphila)]]
 
**[[Pegfilgrastim-jmdb (Fulphila)]]
−
**[[Pegfilgrastim (Cegfila)]]
+
**[[Pegfilgrastim-cegf (Cegfila)]]
−
**[[Pegfilgrastim (Grasustek)]]
+
**[[Pegfilgrastim-gras (Grasustek)]]
−
**[[Pegfilgrastim (Pelgraz)]]
+
**[[Pegfilgrastim-pbbk (Fylnetra)]]
−
**[[Pegfilgrastim (Pelmeg)]]
+
**[[Pegfilgrastim-pelg (Pelgraz)]]
 +
**[[Pegfilgrastim-pelm (Pelmeg)]]
 +
**[[Pegfilgrastim-stim (Stimufend)]]
 
*[[Penicillin V]]
 
*[[Penicillin V]]
 
*[[Pentamidine (Nebupent)]]
 
*[[Pentamidine (Nebupent)]]
Line 930: Line 1,020:
 
*[[Promethazine (Phenergan)]]
 
*[[Promethazine (Phenergan)]]
 
*[[Protamine sulfate]]
 
*[[Protamine sulfate]]
 +
*[[Protein C, human (Ceprotin)]]
 
*[[Prothrombin Complex Concentrate, human]]
 
*[[Prothrombin Complex Concentrate, human]]
  
Line 937: Line 1,028:
  
 
==R==
 
==R==
−
 
−
 
 
*[[Rabeprazole (Aciphex)]]
 
*[[Rabeprazole (Aciphex)]]
 
*[[Raloxifene (Evista)]]
 
*[[Raloxifene (Evista)]]
Line 944: Line 1,033:
 
*[[Ranitidine (Zantac)]]
 
*[[Ranitidine (Zantac)]]
 
*[[Rasburicase (Elitek)]]
 
*[[Rasburicase (Elitek)]]
 +
*[[Remestemcel-L (Prochymal)]]
 
*[[Rho(D) immune globulin (RhoGAM)]]
 
*[[Rho(D) immune globulin (RhoGAM)]]
 
*[[Rilzabrutinib (PRN-1008)]]
 
*[[Rilzabrutinib (PRN-1008)]]
Line 950: Line 1,040:
 
*[[Rolapitant (Varubi)]]
 
*[[Rolapitant (Varubi)]]
 
*[[Romiplostim (Nplate)]]
 
*[[Romiplostim (Nplate)]]
 +
*[[Rusfertide (PTG-300)]]
  
 
==S==
 
==S==
Line 958: Line 1,049:
 
*[[Siltuximab (Sylvant)]]
 
*[[Siltuximab (Sylvant)]]
 
*[[Sirolimus (Rapamune)]]
 
*[[Sirolimus (Rapamune)]]
 +
*[[Sodium thiosulfate (Pedmark)]]
 +
*[[Sutimlimab (Enjaymo)]]
  
 
==T==
 
==T==
Line 963: Line 1,056:
 
*[[Tacrolimus (Prograf)]]
 
*[[Tacrolimus (Prograf)]]
 
*[[Tbo-filgrastim (Granix)]]
 
*[[Tbo-filgrastim (Granix)]]
 +
*[[Telotristat (Xermelo)]]
 
*[[Ticagrelor (Brilinta)]]
 
*[[Ticagrelor (Brilinta)]]
−
*[[Ticlodipine (Ticlid)]]
+
*[[Ticlopidine (Ticlid)]]
 
*[[Tinzaparin (Innohep)]]
 
*[[Tinzaparin (Innohep)]]
 
*[[Tirofiban (Aggrastat)]]
 
*[[Tirofiban (Aggrastat)]]
 
*[[Tocilizumab (Actemra)]]
 
*[[Tocilizumab (Actemra)]]
 +
**[[Tocilizumab-aazg (Tyenne)]]
 +
**[[Tocilizumab-bavi (Tofidence)]]
 
*[[Tofacitinib (Xeljanz)]]
 
*[[Tofacitinib (Xeljanz)]]
 
*[[Tranexamic acid (Cyklokapron)]]
 
*[[Tranexamic acid (Cyklokapron)]]
Line 984: Line 1,080:
 
*[[Valoctocogene roxaparvovec (AAV5-hFVIII-SQ)]]
 
*[[Valoctocogene roxaparvovec (AAV5-hFVIII-SQ)]]
 
*[[Valproate (Depakote)]]
 
*[[Valproate (Depakote)]]
 +
*[[Verbrinacogene setparvovec (FLT-180a)]]
 
*[[von Willebrand factor and factor VIII complex, human]]
 
*[[von Willebrand factor and factor VIII complex, human]]
 
*[[von Willebrand factor, recombinant]]
 
*[[von Willebrand factor, recombinant]]
 +
*[[Vonoprazan (Takecab)]]
 
*[[Vorapaxar (Zontivity)]]
 
*[[Vorapaxar (Zontivity)]]
 
*[[Voriconazole (Vfend)]]
 
*[[Voriconazole (Vfend)]]
Line 998: Line 1,096:
  
 
=By Category=
 
=By Category=
−
''Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).''
+
''Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is an ongoing process so not all of these links are active or current).''
  
 
==[[:Category:REMS_program|Drugs in a REMS program]]==
 
==[[:Category:REMS_program|Drugs in a REMS program]]==
Line 1,145: Line 1,243:
 
*[[:Category:Anal cancer medications|Anal cancer medications]]
 
*[[:Category:Anal cancer medications|Anal cancer medications]]
 
*[[:Category:Anaplastic large cell lymphoma medications|Anaplastic large cell lymphoma medications]]
 
*[[:Category:Anaplastic large cell lymphoma medications|Anaplastic large cell lymphoma medications]]
−
*[[:Category:Basal cell and squamous cell skin cancer medications|Basal cell and squamous cell skin cancer medications]]
 
 
*[[:Category:Bladder cancer medications|Bladder cancer medications]]
 
*[[:Category:Bladder cancer medications|Bladder cancer medications]]
 
*[[:Category:Bone cancer medications |Bone cancer medications]]
 
*[[:Category:Bone cancer medications |Bone cancer medications]]
Line 1,151: Line 1,248:
 
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]]
 
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]]
 
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]]
 
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]]
−
*[[:Category:Castleman’s disease medications|Castleman’s disease medications]]
+
*[[:Category:Castleman disease medications|Castleman disease medications]]
 
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]]
 
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]]
 
*[[:Category:CNS lymphoma medications|Central nervous system (CNS) lymphoma medications]]
 
*[[:Category:CNS lymphoma medications|Central nervous system (CNS) lymphoma medications]]
 
*[[:Category:Cervical cancer medications|Cervical cancer medications]]
 
*[[:Category:Cervical cancer medications|Cervical cancer medications]]
 
*[[:Category:Chronic lymphocytic leukemia medications|Chronic lymphocytic leukemia (CLL/SLL) medications]]
 
*[[:Category:Chronic lymphocytic leukemia medications|Chronic lymphocytic leukemia (CLL/SLL) medications]]
−
*[[:Category:Chronic myelogenous leukemia medications|Chronic myelogenous leukemia medications]]
+
*[[:Category:Chronic myeloid leukemia medications|Chronic myeloid leukemia (CML) medications]]
−
*[[:Category:Chronic myelomonocytic leukemia medications|Chronic myelomonocytic leukemia medications]]
+
*[[:Category:Chronic myelomonocytic leukemia medications|Chronic myelomonocytic leukemia (CMML) medications]]
 
*[[:Category:Colon cancer medications|Colon cancer medications]]
 
*[[:Category:Colon cancer medications|Colon cancer medications]]
 +
*[[:Category:Colorectal cancer medications|Colorectal cancer (CRC) medications]]
 +
*[[:Category:Cutaneous basal cell carcinoma medications|Cutaneous BCC medications]]
 +
*[[:Category:Cutaneous squamous cell carcinoma medications|Cutaneous SCC medications]]
 
*[[:Category:Cutaneous T-cell lymphoma medications|Cutaneous T-cell lymphoma medications]]
 
*[[:Category:Cutaneous T-cell lymphoma medications|Cutaneous T-cell lymphoma medications]]
 
*[[:Category:Diffuse large B-cell lymphoma medications|Diffuse large B-cell lymphoma medications]]
 
*[[:Category:Diffuse large B-cell lymphoma medications|Diffuse large B-cell lymphoma medications]]
Line 1,221: Line 1,321:
 
*[[:Category:Subcutaneous medications|Subcutaneous (SC) medications]]
 
*[[:Category:Subcutaneous medications|Subcutaneous (SC) medications]]
  
−
==Medications by Year of Approval==
+
==Medications by FDA Year of Approval==
  
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
Line 1,294: Line 1,394:
 
*[[:Category:FDA approved in 2018|FDA approved in 2018]]
 
*[[:Category:FDA approved in 2018|FDA approved in 2018]]
 
*[[:Category:FDA approved in 2019|FDA approved in 2019]]
 
*[[:Category:FDA approved in 2019|FDA approved in 2019]]
 +
*[[:Category:FDA approved in 2020|FDA approved in 2020]]
 +
*[[:Category:FDA approved in 2021|FDA approved in 2021]]
 +
*[[:Category:FDA approved in 2022|FDA approved in 2022]]
 +
*[[:Category:FDA approved in 2023|FDA approved in 2023]]
 +
*[[:Category:FDA approved in 2024|FDA approved in 2024]]
 
</div>
 
</div>
  
Line 1,304: Line 1,409:
 
*[https://doi.org/10.1200/JOP.2016.017905 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society (ASCO/ONS) Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology]
 
*[https://doi.org/10.1200/JOP.2016.017905 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society (ASCO/ONS) Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology]
 
*[http://issuu.com/theoncologypharmacist/docs/jhop_march2011/1?mode=a_p Chemotherapy Administration Sequence]<ref>Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. [http://issuu.com/theoncologypharmacist/docs/jhop_march2011/1?mode=a_p link to original article]</ref> - with chemotherapy sequencing chart
 
*[http://issuu.com/theoncologypharmacist/docs/jhop_march2011/1?mode=a_p Chemotherapy Administration Sequence]<ref>Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. [http://issuu.com/theoncologypharmacist/docs/jhop_march2011/1?mode=a_p link to original article]</ref> - with chemotherapy sequencing chart
−
*[https://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01321.x/full The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy.] [https://pubmed.ncbi.nlm.nih.gov/20887505 PubMed]
+
*[https://doi.org/10.1111/j.1743-7563.2010.01321.x The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy.] [https://pubmed.ncbi.nlm.nih.gov/20887505/ PubMed]
 
*[https://crediblemeds.org/ CredibleMeds.org] - lists of QT-prolonging drugs; requires free registration to see full list
 
*[https://crediblemeds.org/ CredibleMeds.org] - lists of QT-prolonging drugs; requires free registration to see full list
 
*[http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm FDA drug shortages list]
 
*[http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm FDA drug shortages list]
Line 1,310: Line 1,415:
 
*[http://dailymed.nlm.nih.gov/dailymed/index.cfm DailyMed] - a comprehensive NLM portal to all FDA-approved drugs
 
*[http://dailymed.nlm.nih.gov/dailymed/index.cfm DailyMed] - a comprehensive NLM portal to all FDA-approved drugs
 
*[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ Drugs@FDA] - the main portal into the FDA drug database
 
*[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ Drugs@FDA] - the main portal into the FDA drug database
−
*[http://www.cancer.gov/drugdictionary The NCI Drug Dictionary] - an extensive resource with most antineoplastics (approved and in clinical trials) listed
+
*[https://www.cancer.gov/drugdictionary The NCI Drug Dictionary] - an extensive resource with most antineoplastics (approved and in clinical trials) listed
 
*[http://blogs.sciencemag.org/pipeline/ In the Pipeline] - a blog from a veteran of the pharmaceutical industry, Derek Lowe. General but much is cancer-relevant. The [http://www.pipeline.corante.com/ old home] of this blog is no longer active.
 
*[http://blogs.sciencemag.org/pipeline/ In the Pipeline] - a blog from a veteran of the pharmaceutical industry, Derek Lowe. General but much is cancer-relevant. The [http://www.pipeline.corante.com/ old home] of this blog is no longer active.
 
*[[Steroid conversions]]
 
*[[Steroid conversions]]

Latest revision as of 11:56, 5 July 2024

Back to Top

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

Other interesting and helpful links can be found by clicking the link.

Chemotherapy safety standards

Dose adjustments

Antimicrobials

Growth factors

Approved antineoplastics

This section contains anticancer drugs that have had at least one formal approval in any domain (FDA, EMA, etc). Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound. For drugs first approved within the current or prior calendar years, the date of initial approval is also provided here.

A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

Q

R

S

T

U

V

Z

Discontinued antineoplastics

This section contains drugs that have had at least one formal approval in any domain (FDA, EMA, etc), but are no longer on the market. Note that it is possible that these drugs continue to be available in some limited way, such as through compassionate use programs.

A

D

E

F

L

M

O

P

S

T

U

V

Investigational antineoplastics

This list is far from exhaustive. Drugs are included here generally once there are some encouraging preliminary results. Since is it very difficult to tell when a company has stopped development on a drug, this list may also include drugs that are no longer under investigation.

A

B

C

D

E

F

G

H

I

J

L

M

N

O

P

Q

R

S

T

U

V

Z

Supportive and other medications

This section contains supportive drugs that are either approved or investigational. Biosimilars are also indexed here, indented below their parent compound. Note that EMA biosimilar approvals do not include the four-letter suffix at this time, which we have added to distinguish the generic ingredient from the parent compound.

A

B

C

D

E

F

G

H

I

L

M

N

O

P

Q

R

S

T

U

V

W

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is an ongoing process so not all of these links are active or current).

Drugs in a REMS program

Cytotoxic Chemotherapy

Kinase inhibitors

Endocrine therapy

Investigational and Discontinued

Biologics

Supportive Medications

Radioactive agents

Benign Hematology Medications

Hematopoietic Growth Factors

Miscellaneous

Medications by Condition

Medications by Route of Administration

Medications by FDA Year of Approval

Interesting and Helpful Links

References

  1. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  2. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=88292"